Clin Oncol (R Coll Radiol) 2017 Oct 13
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.   
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.

Related Questions

Would you offer 3-5 fractions for larger lesions instead or would you favor more traditional standard fractionation regimens?

I have seen small amounts of evidence for V4<20cc and V14<7cc, but overall it seems like there is little published on this issue.  

Is there a role for SRS/fSRS?